FLASCO

 

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver

Latest News

FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL

On June 13, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. Approval was based on data from 53 patients with relapsed or...

New indication for VENCLEXTA(R) (venetoclax tablets)

On June 8, 2018, VENCLEXTA® (venetoclax tablets) was approved by the US Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Genentech BioOncology® Access Solutions is your resource for access and...

UF Health

UF Health Cancer Center Navigator Referring Physician Resource

Connect with the UF Health Cancer Center Stay in the know. See what the UF Health Cancer Center is doing when you sign up to receive news and updates, information about current clinical trials, our magazine and our annual report. View full newsletter here. Subscribe to Cancer Center News here.

FDA approves bevacizumab for ovarian cancer and pembrolizumab for large B-cell lymphoma cancer

Bevacizumab for Ovarian Cancer On June 13, 2018, the Food and Drug Administration approved bevacizumab (Avastin®, Genentech, Inc.) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. Approval was based on GOG-0218 (NCT00262847),...

FDA Approves New Treatment for Women with Advanced Ovarian Cancer After Initial Surgery

Today, the FDA granted approval to Avastin in combination with chemotherapy, followed by Avastin alone, for the treatment of women with advanced (stage III or IV) ovarian cancer after initial surgery. The Genentech press release including Important Safety Information is linked here. This approval marks an important milestone in ovarian cancer, as this is the...

Who’s Online

There are no users currently online